摘要
目的比较艾司唑仑与氯硝西泮辅助利培酮治疗分裂症患者阳性症状的疗效和安全性。方法将61例予利培酮治疗的精神分裂症患者随机分为Ⅰ组(n=31)和Ⅱ组(n=30)。Ⅰ、Ⅱ组初期辅助治疗分别使用艾司唑仑与氯硝西泮,每8h注射1次,2mg,两组疗程均为2周。使用简明精神症状量表(BPRS)于治疗前及治疗第二周末各评定1次临床疗效;通过副反应量表(TESS)、实验室检查、生命体征等观察药物安全性。结果治疗2周后,艾司唑仑组BPRS总分减分为(41.18±2.67),氯硝西泮组为(40.99±2.39),两组差异无显著性。两组不良反应仅后遗效应差异有显著性。结论注射用艾司唑仑与氯硝西泮辅助治疗分裂症患者阳性症状的疗效总体相当,但艾司唑仑在后遗效应方面有优势。
OBJECTIVE To study the efficacy and safety of estazolam and clonazepam in treating patients with schizophrenia. METHODS A total of 61 Schizophrenias with excitement and agitation were randomly divided into estazolam group （n = 31） and clonazepam group（n = 30） for the treatment of 2 weeks. The patients were assessed with the Brief Psychiatric Rating Scale （BPRS）and Treatment Emergent Symptom Scale （TESS）. RESULTS At the end of 2 weeks, the total scores of BPRS of group Ⅰ （41.18 ± 2.67）and group Ⅱ （40.99 ± 2.39） were both significantly decreased. Between two groups, the efficacy had no significant differences hut side effects had. CONCLUSION Estazolam and clonazepam had significant curative efficacy, milderadverse effects and higher safety for treating acute phase of patients with schizophrenia.
出处
《海峡药学》
2009年第5期114-116,共3页
Strait Pharmaceutical Journal
